Stephen Dreskin
Concepts (475)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peanut Hypersensitivity | 27 | 2025 | 146 | 7.390 |
Why?
| | Immunoglobulin E | 42 | 2025 | 341 | 6.560 |
Why?
| | Antigens, Plant | 23 | 2025 | 54 | 6.010 |
Why?
| | 2S Albumins, Plant | 20 | 2025 | 31 | 5.860 |
Why?
| | Allergens | 23 | 2023 | 407 | 5.120 |
Why?
| | Arachis | 19 | 2023 | 112 | 4.320 |
Why?
| | Glycoproteins | 12 | 2016 | 345 | 2.780 |
Why?
| | Epitopes | 9 | 2025 | 481 | 2.560 |
Why?
| | Urticaria | 11 | 2018 | 38 | 2.540 |
Why?
| | Mast Cells | 13 | 2021 | 146 | 1.530 |
Why?
| | Omalizumab | 3 | 2024 | 51 | 1.520 |
Why?
| | Basophils | 14 | 2018 | 73 | 1.480 |
Why?
| | Desensitization, Immunologic | 3 | 2019 | 94 | 1.080 |
Why?
| | Food Hypersensitivity | 3 | 2020 | 183 | 0.870 |
Why?
| | Benzoquinones | 4 | 2007 | 48 | 0.810 |
Why?
| | Nuts | 2 | 2023 | 12 | 0.750 |
Why?
| | Anti-Allergic Agents | 3 | 2018 | 46 | 0.690 |
Why?
| | Anaphylaxis | 3 | 2018 | 105 | 0.690 |
Why?
| | Receptors, IgE | 11 | 2003 | 45 | 0.680 |
Why?
| | Seeds | 1 | 2020 | 86 | 0.660 |
Why?
| | Amino Acid Sequence | 8 | 2025 | 2146 | 0.660 |
Why?
| | Plant Proteins | 6 | 2023 | 114 | 0.650 |
Why?
| | Peptide Library | 2 | 2017 | 88 | 0.640 |
Why?
| | Amino Acids | 1 | 2023 | 503 | 0.640 |
Why?
| | Peptide Mapping | 1 | 2019 | 64 | 0.640 |
Why?
| | Allergists | 1 | 2018 | 12 | 0.600 |
Why?
| | Protein Conformation | 5 | 2022 | 930 | 0.580 |
Why?
| | Peptides | 7 | 2025 | 985 | 0.570 |
Why?
| | Allergy and Immunology | 1 | 2018 | 43 | 0.570 |
Why?
| | Immunoglobulin G | 7 | 2022 | 886 | 0.550 |
Why?
| | Rhinitis, Allergic, Seasonal | 3 | 2008 | 29 | 0.540 |
Why?
| | Plant Extracts | 3 | 2018 | 203 | 0.530 |
Why?
| | Bortezomib | 1 | 2016 | 54 | 0.520 |
Why?
| | Anti-Inflammatory Agents | 4 | 2008 | 498 | 0.500 |
Why?
| | Drug Hypersensitivity | 2 | 2013 | 89 | 0.490 |
Why?
| | Protein Binding | 6 | 2025 | 2229 | 0.490 |
Why?
| | Antibodies, Anti-Idiotypic | 2 | 2014 | 59 | 0.480 |
Why?
| | Interleukin-5 | 2 | 2008 | 45 | 0.480 |
Why?
| | Epitope Mapping | 3 | 2025 | 62 | 0.470 |
Why?
| | Hypersensitivity, Immediate | 4 | 2013 | 44 | 0.470 |
Why?
| | Humans | 73 | 2025 | 137509 | 0.460 |
Why?
| | Models, Molecular | 2 | 2016 | 1586 | 0.430 |
Why?
| | Proteome | 1 | 2018 | 474 | 0.420 |
Why?
| | Cell Degranulation | 3 | 2014 | 42 | 0.410 |
Why?
| | Animals | 33 | 2022 | 37009 | 0.400 |
Why?
| | Cross Reactions | 4 | 2023 | 133 | 0.390 |
Why?
| | Pharmacy Service, Hospital | 1 | 2013 | 91 | 0.380 |
Why?
| | Autoimmunity | 3 | 2013 | 907 | 0.370 |
Why?
| | Clinical Protocols | 1 | 2013 | 268 | 0.360 |
Why?
| | Compensation and Redress | 1 | 2011 | 7 | 0.360 |
Why?
| | National Health Programs | 1 | 2011 | 21 | 0.360 |
Why?
| | Autoimmune Diseases | 2 | 2013 | 459 | 0.350 |
Why?
| | Phosphatidylinositols | 6 | 1995 | 57 | 0.340 |
Why?
| | Influenza Vaccines | 3 | 2013 | 551 | 0.340 |
Why?
| | B-Lymphocytes | 1 | 2016 | 848 | 0.340 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2010 | 86 | 0.340 |
Why?
| | Leukemia, Basophilic, Acute | 5 | 1995 | 5 | 0.330 |
Why?
| | Hydroxyproline | 2 | 2023 | 21 | 0.330 |
Why?
| | Rats | 16 | 2015 | 5676 | 0.330 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 228 | 0.320 |
Why?
| | Antibodies | 1 | 2011 | 414 | 0.310 |
Why?
| | Thyroid Gland | 2 | 2009 | 94 | 0.310 |
Why?
| | Immune Tolerance | 1 | 2011 | 362 | 0.310 |
Why?
| | Chronic Disease | 8 | 2018 | 1790 | 0.300 |
Why?
| | Type C Phospholipases | 5 | 1995 | 75 | 0.300 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 807 | 0.290 |
Why?
| | Thimerosal | 1 | 2007 | 6 | 0.290 |
Why?
| | Eosinophils | 2 | 2021 | 331 | 0.290 |
Why?
| | Phagocyte Bactericidal Dysfunction | 4 | 1987 | 12 | 0.270 |
Why?
| | Job Syndrome | 4 | 1987 | 7 | 0.270 |
Why?
| | Bone Marrow Cells | 2 | 2016 | 313 | 0.260 |
Why?
| | HLA-D Antigens | 1 | 2006 | 34 | 0.250 |
Why?
| | Receptors, Fc | 4 | 1991 | 53 | 0.250 |
Why?
| | Disease Models, Animal | 7 | 2018 | 4295 | 0.250 |
Why?
| | Leukotrienes | 1 | 2006 | 37 | 0.250 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 69 | 0.240 |
Why?
| | Angioedema | 2 | 2010 | 16 | 0.240 |
Why?
| | Hypersensitivity | 3 | 2008 | 256 | 0.240 |
Why?
| | Cell Line | 8 | 2019 | 2852 | 0.240 |
Why?
| | Isoenzymes | 2 | 2003 | 305 | 0.230 |
Why?
| | RNA, Messenger | 4 | 2007 | 2838 | 0.230 |
Why?
| | Vaccination | 2 | 2011 | 1398 | 0.230 |
Why?
| | Transcriptional Activation | 1 | 2007 | 379 | 0.230 |
Why?
| | Adenosine Triphosphate | 4 | 1995 | 487 | 0.230 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2901 | 0.230 |
Why?
| | Interferon-gamma | 1 | 2008 | 790 | 0.220 |
Why?
| | Tumor Cells, Cultured | 8 | 2003 | 957 | 0.220 |
Why?
| | Down-Regulation | 2 | 2006 | 658 | 0.220 |
Why?
| | Immunologic Tests | 1 | 2024 | 16 | 0.220 |
Why?
| | Biomarkers | 3 | 2024 | 4172 | 0.220 |
Why?
| | Skin Tests | 4 | 2013 | 101 | 0.210 |
Why?
| | Cell Nucleus | 1 | 2007 | 615 | 0.210 |
Why?
| | Pistacia | 1 | 2023 | 2 | 0.210 |
Why?
| | Anacardium | 1 | 2023 | 3 | 0.210 |
Why?
| | Juglans | 1 | 2023 | 7 | 0.200 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2003 | 79 | 0.200 |
Why?
| | Hospitalization | 1 | 2013 | 2197 | 0.200 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2193 | 0.200 |
Why?
| | NF-kappa B | 1 | 2007 | 694 | 0.200 |
Why?
| | Alanine | 1 | 2023 | 153 | 0.200 |
Why?
| | Hypergammaglobulinemia | 3 | 1987 | 9 | 0.200 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1800 | 0.200 |
Why?
| | Arachidonate 5-Lipoxygenase | 2 | 2006 | 43 | 0.190 |
Why?
| | Bone Marrow | 3 | 2021 | 286 | 0.190 |
Why?
| | Nasal Mucosa | 1 | 2002 | 109 | 0.190 |
Why?
| | Basophil Degranulation Test | 3 | 2012 | 6 | 0.190 |
Why?
| | Mice | 9 | 2022 | 17843 | 0.180 |
Why?
| | Child, Preschool | 8 | 2019 | 11094 | 0.180 |
Why?
| | Detergents | 1 | 2001 | 44 | 0.180 |
Why?
| | Common Variable Immunodeficiency | 1 | 2001 | 29 | 0.180 |
Why?
| | Cytological Techniques | 1 | 2001 | 27 | 0.180 |
Why?
| | Histamine | 3 | 2012 | 68 | 0.180 |
Why?
| | Sesamum | 1 | 2020 | 6 | 0.180 |
Why?
| | Female | 23 | 2019 | 73160 | 0.170 |
Why?
| | Middle Aged | 15 | 2015 | 33353 | 0.170 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 3 | 1991 | 37 | 0.170 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2001 | 73 | 0.170 |
Why?
| | Ethnopharmacology | 1 | 2000 | 1 | 0.170 |
Why?
| | Cell Membrane | 5 | 1995 | 751 | 0.170 |
Why?
| | Drugs, Chinese Herbal | 1 | 2000 | 21 | 0.170 |
Why?
| | Antigens | 3 | 1996 | 358 | 0.170 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 107 | 0.170 |
Why?
| | Antibodies, Monoclonal | 2 | 2019 | 1428 | 0.160 |
Why?
| | Pneumonia | 1 | 2006 | 638 | 0.160 |
Why?
| | Phosphoenolpyruvate | 3 | 1995 | 3 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2007 | 1242 | 0.160 |
Why?
| | Immunoblotting | 2 | 2011 | 307 | 0.160 |
Why?
| | Enzyme Activation | 6 | 2001 | 816 | 0.160 |
Why?
| | Adult | 16 | 2015 | 37818 | 0.160 |
Why?
| | Histocompatibility Antigens | 2 | 2013 | 107 | 0.160 |
Why?
| | Nonprescription Drugs | 1 | 2000 | 66 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2001 | 316 | 0.160 |
Why?
| | Monocytes | 2 | 2007 | 568 | 0.160 |
Why?
| | Adhesins, Escherichia coli | 1 | 1999 | 1 | 0.160 |
Why?
| | Dyspnea | 1 | 2001 | 251 | 0.160 |
Why?
| | Fimbriae Proteins | 1 | 1999 | 20 | 0.150 |
Why?
| | Mycoses | 1 | 2000 | 80 | 0.150 |
Why?
| | Inflammation | 3 | 2007 | 2838 | 0.150 |
Why?
| | Gastrointestinal Tract | 1 | 2021 | 194 | 0.150 |
Why?
| | Adhesins, Bacterial | 1 | 1999 | 40 | 0.150 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 2 | 2009 | 114 | 0.140 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2009 | 144 | 0.140 |
Why?
| | Awards and Prizes | 1 | 2018 | 68 | 0.140 |
Why?
| | History, 21st Century | 1 | 2018 | 211 | 0.140 |
Why?
| | Triamcinolone | 1 | 1997 | 17 | 0.140 |
Why?
| | Myoclonus | 1 | 1997 | 15 | 0.140 |
Why?
| | Binding Sites | 2 | 2016 | 1310 | 0.140 |
Why?
| | Phosphocreatine | 2 | 1995 | 47 | 0.130 |
Why?
| | Sinusitis | 1 | 2000 | 221 | 0.130 |
Why?
| | Administration, Oral | 1 | 2019 | 814 | 0.130 |
Why?
| | History, 20th Century | 1 | 2018 | 324 | 0.130 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1997 | 41 | 0.130 |
Why?
| | Molecular Mimicry | 1 | 2017 | 40 | 0.130 |
Why?
| | Lidocaine | 1 | 1997 | 42 | 0.130 |
Why?
| | Calcimycin | 1 | 1996 | 49 | 0.130 |
Why?
| | Anesthetics, Local | 1 | 1997 | 80 | 0.130 |
Why?
| | Consensus Sequence | 1 | 2016 | 73 | 0.130 |
Why?
| | Skin | 1 | 2021 | 751 | 0.130 |
Why?
| | Cell Surface Display Techniques | 1 | 2016 | 12 | 0.130 |
Why?
| | Arachidonic Acid | 1 | 1996 | 120 | 0.130 |
Why?
| | Adolescent | 9 | 2019 | 21552 | 0.120 |
Why?
| | Leukocyte Common Antigens | 1 | 2016 | 87 | 0.120 |
Why?
| | Male | 14 | 2019 | 67715 | 0.120 |
Why?
| | Magnesium | 2 | 1993 | 159 | 0.120 |
Why?
| | Immunophenotyping | 2 | 2016 | 321 | 0.120 |
Why?
| | Chemokine CCL2 | 1 | 2016 | 117 | 0.120 |
Why?
| | B-Lymphocyte Subsets | 1 | 2016 | 75 | 0.120 |
Why?
| | Adoptive Transfer | 1 | 2016 | 224 | 0.120 |
Why?
| | Bacteriophages | 1 | 2017 | 95 | 0.120 |
Why?
| | Child | 10 | 2015 | 22034 | 0.120 |
Why?
| | Cytokines | 5 | 2018 | 2095 | 0.120 |
Why?
| | Protein Array Analysis | 1 | 2015 | 57 | 0.110 |
Why?
| | Mice, Inbred BALB C | 3 | 2006 | 1271 | 0.110 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2013 | 152 | 0.110 |
Why?
| | Lung Diseases | 1 | 2001 | 768 | 0.110 |
Why?
| | Prostaglandin D2 | 3 | 2006 | 23 | 0.110 |
Why?
| | Tryptases | 2 | 2012 | 12 | 0.110 |
Why?
| | Antigens, Dermatophagoides | 1 | 2014 | 10 | 0.110 |
Why?
| | Chromatography, Liquid | 2 | 2023 | 433 | 0.110 |
Why?
| | gamma-Tocopherol | 1 | 2014 | 8 | 0.110 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 252 | 0.110 |
Why?
| | Cyclooxygenase 2 | 2 | 2006 | 178 | 0.110 |
Why?
| | Lung Transplantation | 1 | 1997 | 309 | 0.110 |
Why?
| | Vitamin E | 1 | 2014 | 122 | 0.110 |
Why?
| | Genes, fos | 1 | 1993 | 36 | 0.110 |
Why?
| | Cats | 2 | 2004 | 211 | 0.100 |
Why?
| | Cluster Analysis | 1 | 2015 | 503 | 0.100 |
Why?
| | Tandem Mass Spectrometry | 2 | 2023 | 533 | 0.100 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 654 | 0.100 |
Why?
| | Macrophages | 1 | 2001 | 1548 | 0.100 |
Why?
| | Headache | 1 | 2014 | 154 | 0.100 |
Why?
| | Asthma | 1 | 2006 | 2290 | 0.100 |
Why?
| | Pichia | 1 | 2012 | 22 | 0.100 |
Why?
| | Diagnosis, Differential | 4 | 2008 | 1486 | 0.100 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 346 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 974 | 0.090 |
Why?
| | Mutant Proteins | 1 | 2012 | 101 | 0.090 |
Why?
| | Albumins | 2 | 2023 | 114 | 0.090 |
Why?
| | Transfection | 2 | 2007 | 948 | 0.090 |
Why?
| | Complex Mixtures | 1 | 2011 | 11 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 784 | 0.090 |
Why?
| | Blotting, Western | 2 | 2007 | 1227 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 3 | 2010 | 2420 | 0.090 |
Why?
| | Proteomics | 1 | 2018 | 1113 | 0.090 |
Why?
| | Histamine Release | 3 | 2013 | 21 | 0.090 |
Why?
| | Lipopolysaccharides | 2 | 2007 | 886 | 0.090 |
Why?
| | Phosphoric Diester Hydrolases | 2 | 2006 | 46 | 0.080 |
Why?
| | Algorithms | 2 | 2008 | 1703 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2018 | 3546 | 0.080 |
Why?
| | Pharmacists | 1 | 2013 | 260 | 0.080 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 77 | 0.080 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 112 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2007 | 849 | 0.080 |
Why?
| | Antibody Formation | 1 | 2011 | 299 | 0.080 |
Why?
| | Medical Records | 1 | 2010 | 173 | 0.080 |
Why?
| | Siblings | 1 | 2010 | 228 | 0.080 |
Why?
| | Autoantibodies | 2 | 2009 | 1501 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 395 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2066 | 0.080 |
Why?
| | Chromatography, Gel | 1 | 2009 | 127 | 0.080 |
Why?
| | Gene Frequency | 1 | 2010 | 521 | 0.080 |
Why?
| | Ovalbumin | 2 | 2006 | 183 | 0.080 |
Why?
| | Molecular Weight | 1 | 2009 | 332 | 0.080 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2010 | 368 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1047 | 0.080 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2009 | 73 | 0.080 |
Why?
| | Haplotypes | 1 | 2010 | 491 | 0.080 |
Why?
| | Aged | 4 | 2015 | 23795 | 0.070 |
Why?
| | Diphenhydramine | 1 | 2008 | 37 | 0.070 |
Why?
| | Cytoplasm | 1 | 1989 | 274 | 0.070 |
Why?
| | Histamine H1 Antagonists | 1 | 2008 | 30 | 0.070 |
Why?
| | Th2 Cells | 2 | 2006 | 176 | 0.070 |
Why?
| | Infant | 5 | 2013 | 9464 | 0.070 |
Why?
| | Administration, Intranasal | 1 | 2008 | 90 | 0.070 |
Why?
| | Phenotype | 1 | 2016 | 3205 | 0.070 |
Why?
| | Young Adult | 3 | 2015 | 13241 | 0.070 |
Why?
| | Epinephrine | 1 | 2008 | 145 | 0.070 |
Why?
| | Escherichia coli | 1 | 2012 | 815 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2005 | 1167 | 0.070 |
Why?
| | Interleukin-4 | 1 | 2008 | 217 | 0.070 |
Why?
| | Abscess | 1 | 1987 | 76 | 0.070 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 26 | 0.070 |
Why?
| | HMGB1 Protein | 1 | 2007 | 50 | 0.070 |
Why?
| | Polysaccharides, Bacterial | 1 | 2007 | 71 | 0.070 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2007 | 74 | 0.070 |
Why?
| | Immunotherapy | 2 | 2009 | 647 | 0.070 |
Why?
| | United States | 4 | 2018 | 14695 | 0.070 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2007 | 85 | 0.060 |
Why?
| | Immunoprecipitation | 1 | 2007 | 155 | 0.060 |
Why?
| | Lysine | 2 | 2001 | 297 | 0.060 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2006 | 10 | 0.060 |
Why?
| | Transcription Factor RelA | 1 | 2007 | 88 | 0.060 |
Why?
| | Cyclooxygenase 1 | 1 | 2006 | 27 | 0.060 |
Why?
| | Nigella sativa | 1 | 2006 | 1 | 0.060 |
Why?
| | Endotoxins | 1 | 2007 | 220 | 0.060 |
Why?
| | Goblet Cells | 1 | 2006 | 22 | 0.060 |
Why?
| | Pyrophosphatases | 1 | 2006 | 28 | 0.060 |
Why?
| | Dermatitis, Atopic | 1 | 2009 | 328 | 0.060 |
Why?
| | Serum | 1 | 2006 | 59 | 0.060 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2005 | 15 | 0.060 |
Why?
| | Plasmids | 1 | 2007 | 363 | 0.060 |
Why?
| | Alopecia Areata | 1 | 2005 | 13 | 0.060 |
Why?
| | Immunochemistry | 1 | 2005 | 14 | 0.060 |
Why?
| | Bronchial Hyperreactivity | 1 | 2006 | 111 | 0.060 |
Why?
| | Staphylococcal Infections | 2 | 1987 | 402 | 0.060 |
Why?
| | Vitiligo | 1 | 2005 | 42 | 0.060 |
Why?
| | Time Factors | 3 | 2011 | 6817 | 0.060 |
Why?
| | Haptens | 2 | 1996 | 22 | 0.060 |
Why?
| | Thyroid Hormones | 1 | 2005 | 61 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1351 | 0.060 |
Why?
| | Leukocyte Count | 1 | 2006 | 331 | 0.060 |
Why?
| | Environmental Exposure | 2 | 2009 | 575 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 1008 | 0.060 |
Why?
| | Toll-Like Receptors | 1 | 2006 | 186 | 0.060 |
Why?
| | Biological Assay | 1 | 2005 | 123 | 0.060 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3420 | 0.060 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2001 | 434 | 0.060 |
Why?
| | Staphylococcus aureus | 2 | 1987 | 452 | 0.060 |
Why?
| | Physicians | 1 | 2013 | 904 | 0.050 |
Why?
| | Antibodies, Bacterial | 1 | 1985 | 146 | 0.050 |
Why?
| | Sequence Alignment | 2 | 2014 | 345 | 0.050 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2003 | 21 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 1985 | 210 | 0.050 |
Why?
| | Immunologic Techniques | 1 | 2003 | 40 | 0.050 |
Why?
| | Nut Hypersensitivity | 1 | 2023 | 5 | 0.050 |
Why?
| | Vaccines | 1 | 2008 | 411 | 0.050 |
Why?
| | Up-Regulation | 1 | 2006 | 846 | 0.050 |
Why?
| | Antibody Specificity | 2 | 2003 | 189 | 0.050 |
Why?
| | Lung | 2 | 2006 | 4066 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 845 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2838 | 0.050 |
Why?
| | Cell Count | 2 | 2021 | 321 | 0.050 |
Why?
| | Promoter Regions, Genetic | 1 | 2007 | 1255 | 0.050 |
Why?
| | Signal Transduction | 4 | 2007 | 5096 | 0.050 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2021 | 10 | 0.050 |
Why?
| | MAP Kinase Kinase Kinase 3 | 1 | 2001 | 4 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 10 | 1 | 2001 | 3 | 0.050 |
Why?
| | Octoxynol | 1 | 2001 | 13 | 0.050 |
Why?
| | MAP Kinase Kinase Kinase 2 | 1 | 2001 | 12 | 0.050 |
Why?
| | Mastocytosis | 1 | 2021 | 12 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2001 | 16 | 0.050 |
Why?
| | Precipitin Tests | 1 | 2001 | 100 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 9 | 1 | 2001 | 18 | 0.050 |
Why?
| | Immune Sera | 1 | 2001 | 88 | 0.050 |
Why?
| | Enzyme Stability | 1 | 2001 | 73 | 0.040 |
Why?
| | Biopsy | 2 | 2021 | 1132 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3292 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2014 | 10821 | 0.040 |
Why?
| | Valine | 1 | 2001 | 82 | 0.040 |
Why?
| | Hydrolysis | 2 | 1993 | 191 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 163 | 0.040 |
Why?
| | Exocytosis | 2 | 1993 | 89 | 0.040 |
Why?
| | Serine | 1 | 2001 | 141 | 0.040 |
Why?
| | Bacterial Infections | 1 | 1983 | 251 | 0.040 |
Why?
| | Leukemia | 1 | 1983 | 238 | 0.040 |
Why?
| | T-Lymphocytes | 2 | 2018 | 2000 | 0.040 |
Why?
| | Shock, Septic | 1 | 1983 | 221 | 0.040 |
Why?
| | Medicine, Traditional | 1 | 2000 | 24 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2007 | 1458 | 0.040 |
Why?
| | Gastritis | 1 | 2021 | 108 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2001 | 377 | 0.040 |
Why?
| | Radioallergosorbent Test | 1 | 2000 | 3 | 0.040 |
Why?
| | Environmental Illness | 1 | 2000 | 3 | 0.040 |
Why?
| | Catalysis | 1 | 2001 | 319 | 0.040 |
Why?
| | Enteritis | 1 | 2021 | 103 | 0.040 |
Why?
| | Hypersensitivity, Delayed | 1 | 2000 | 28 | 0.040 |
Why?
| | Growth Hormone | 1 | 1980 | 101 | 0.040 |
Why?
| | Interleukin-3 | 2 | 1989 | 25 | 0.040 |
Why?
| | Protein Domains | 1 | 2021 | 290 | 0.040 |
Why?
| | Mannose | 1 | 1999 | 26 | 0.040 |
Why?
| | Calcium | 3 | 1991 | 1233 | 0.040 |
Why?
| | Eosinophilia | 1 | 2021 | 218 | 0.040 |
Why?
| | Muscles | 1 | 1980 | 325 | 0.040 |
Why?
| | Serotonin | 1 | 2001 | 324 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 1999 | 272 | 0.040 |
Why?
| | Prevalence | 1 | 2005 | 2717 | 0.040 |
Why?
| | Ribosomes | 1 | 1980 | 174 | 0.040 |
Why?
| | Drug Prescriptions | 1 | 2000 | 251 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1950 | 0.040 |
Why?
| | Subdural Space | 1 | 1997 | 8 | 0.030 |
Why?
| | Injections, Epidural | 1 | 1997 | 26 | 0.030 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 325 | 0.030 |
Why?
| | Leukotriene C4 | 1 | 1996 | 11 | 0.030 |
Why?
| | Phosphorylation | 1 | 2001 | 1762 | 0.030 |
Why?
| | Latex | 1 | 1996 | 9 | 0.030 |
Why?
| | Rubber | 1 | 1996 | 7 | 0.030 |
Why?
| | Antibody Affinity | 1 | 1996 | 60 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 5772 | 0.030 |
Why?
| | Steroids | 1 | 1997 | 167 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2001 | 640 | 0.030 |
Why?
| | Hypotension | 1 | 1997 | 123 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2018 | 514 | 0.030 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 1 | 1995 | 11 | 0.030 |
Why?
| | Cell Fractionation | 2 | 1989 | 56 | 0.030 |
Why?
| | Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1995 | 15 | 0.030 |
Why?
| | Vanadates | 1 | 1995 | 14 | 0.030 |
Why?
| | Double-Blind Method | 3 | 2006 | 1987 | 0.030 |
Why?
| | Oligonucleotides | 1 | 1996 | 149 | 0.030 |
Why?
| | Drug Interactions | 1 | 1996 | 409 | 0.030 |
Why?
| | Hydroxylation | 1 | 2014 | 42 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 1995 | 82 | 0.030 |
Why?
| | Leukotriene D4 | 1 | 2014 | 1 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 2004 | 82 | 0.030 |
Why?
| | Dinitrobenzenes | 1 | 1993 | 5 | 0.030 |
Why?
| | Phosphotyrosine | 1 | 1993 | 38 | 0.030 |
Why?
| | Receptor Aggregation | 1 | 1993 | 11 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 2012 | 1357 | 0.030 |
Why?
| | Adenosine | 1 | 1995 | 227 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2001 | 1980 | 0.030 |
Why?
| | Mass Vaccination | 1 | 2013 | 16 | 0.030 |
Why?
| | Tyrosine | 1 | 1993 | 224 | 0.020 |
Why?
| | Permeability | 1 | 1993 | 162 | 0.020 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2013 | 78 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 2 | 2004 | 66 | 0.020 |
Why?
| | Leukocytes | 1 | 1974 | 311 | 0.020 |
Why?
| | Circular Dichroism | 1 | 2012 | 151 | 0.020 |
Why?
| | Protein Kinase C | 1 | 1993 | 265 | 0.020 |
Why?
| | Clone Cells | 1 | 2012 | 266 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1993 | 1108 | 0.020 |
Why?
| | Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1991 | 4 | 0.020 |
Why?
| | Phosphoinositide Phospholipase C | 1 | 1991 | 5 | 0.020 |
Why?
| | Point Mutation | 1 | 2012 | 234 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 1991 | 82 | 0.020 |
Why?
| | Kinetics | 1 | 2014 | 1679 | 0.020 |
Why?
| | Phosphoproteins | 1 | 1993 | 338 | 0.020 |
Why?
| | Air Pollutants | 1 | 1996 | 428 | 0.020 |
Why?
| | Protein Folding | 1 | 2012 | 282 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1991 | 434 | 0.020 |
Why?
| | DNA | 2 | 1996 | 1460 | 0.020 |
Why?
| | Pruritus | 1 | 2010 | 63 | 0.020 |
Why?
| | Pemphigus | 1 | 2009 | 8 | 0.020 |
Why?
| | Rosette Formation | 1 | 1989 | 16 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 1989 | 11 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2004 | 1185 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1995 | 895 | 0.020 |
Why?
| | Extracellular Space | 1 | 1989 | 121 | 0.020 |
Why?
| | Thyroxine | 1 | 2009 | 62 | 0.020 |
Why?
| | Psoriasis | 1 | 2009 | 102 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2009 | 164 | 0.020 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 1988 | 40 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2008 | 138 | 0.020 |
Why?
| | Body Fluid Compartments | 1 | 1987 | 6 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2072 | 0.020 |
Why?
| | Ribonucleases | 2 | 1980 | 55 | 0.020 |
Why?
| | Metabolic Clearance Rate | 1 | 1987 | 117 | 0.020 |
Why?
| | Influenza, Human | 1 | 2013 | 632 | 0.020 |
Why?
| | Dermatitis, Contact | 1 | 1987 | 17 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 767 | 0.020 |
Why?
| | Rhinometry, Acoustic | 1 | 2006 | 1 | 0.020 |
Why?
| | IgG Deficiency | 1 | 2006 | 7 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2010 | 949 | 0.020 |
Why?
| | Bronchial Provocation Tests | 1 | 2006 | 51 | 0.020 |
Why?
| | Necrosis | 1 | 2007 | 244 | 0.020 |
Why?
| | Psychometrics | 1 | 2010 | 723 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2007 | 269 | 0.020 |
Why?
| | Cells, Cultured | 3 | 2007 | 4207 | 0.020 |
Why?
| | Dinoprostone | 1 | 2006 | 191 | 0.020 |
Why?
| | Serine Endopeptidases | 1 | 2006 | 123 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1060 | 0.010 |
Why?
| | Immunoglobulin A, Secretory | 1 | 1985 | 9 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1997 | 2641 | 0.010 |
Why?
| | Immunoglobulin D | 1 | 1985 | 30 | 0.010 |
Why?
| | Granulomatous Disease, Chronic | 1 | 1985 | 55 | 0.010 |
Why?
| | Haemophilus Infections | 1 | 1985 | 42 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2006 | 561 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2009 | 832 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 1985 | 288 | 0.010 |
Why?
| | Agranulocytosis | 1 | 1983 | 30 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2007 | 778 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2756 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1999 | 3708 | 0.010 |
Why?
| | Peritonitis | 1 | 1983 | 84 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 6058 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2004 | 480 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7591 | 0.010 |
Why?
| | Hypophysectomy | 1 | 1980 | 15 | 0.010 |
Why?
| | Puromycin | 1 | 1980 | 10 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 1 | 1980 | 41 | 0.010 |
Why?
| | Peptide Biosynthesis | 1 | 1980 | 13 | 0.010 |
Why?
| | Thy-1 Antigens | 1 | 1999 | 11 | 0.010 |
Why?
| | Concanavalin A | 1 | 1999 | 76 | 0.010 |
Why?
| | Leucine | 1 | 1980 | 111 | 0.010 |
Why?
| | CD28 Antigens | 1 | 1999 | 53 | 0.010 |
Why?
| | Mitogens | 1 | 1999 | 61 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 5138 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 1999 | 264 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2615 | 0.010 |
Why?
| | Serotonin Antagonists | 1 | 1996 | 32 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2003 | 1093 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 211 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1999 | 720 | 0.010 |
Why?
| | Photomicrography | 1 | 1974 | 7 | 0.010 |
Why?
| | Nucleic Acid Denaturation | 1 | 1974 | 32 | 0.010 |
Why?
| | Aspergillus | 1 | 1974 | 16 | 0.010 |
Why?
| | Methods | 1 | 1974 | 65 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1974 | 24 | 0.010 |
Why?
| | Ligands | 1 | 1996 | 665 | 0.010 |
Why?
| | Chromatography, Ion Exchange | 1 | 1974 | 54 | 0.010 |
Why?
| | Histocytochemistry | 1 | 1974 | 82 | 0.010 |
Why?
| | Spectrophotometry | 1 | 1974 | 61 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1974 | 177 | 0.010 |
Why?
| | Freezing | 1 | 1974 | 91 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1974 | 146 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 1996 | 720 | 0.010 |
Why?
| | DNA, Single-Stranded | 1 | 1974 | 118 | 0.010 |
Why?
| | Base Sequence | 1 | 1996 | 2180 | 0.010 |
Why?
| | Pancreas | 1 | 1974 | 328 | 0.010 |
Why?
| | Hot Temperature | 1 | 1974 | 409 | 0.010 |
Why?
| | Chromatin | 1 | 1974 | 524 | 0.010 |
Why?
| | RNA | 1 | 1996 | 924 | 0.000 |
Why?
| | Interphase | 1 | 1989 | 32 | 0.000 |
Why?
| | Ethanol | 1 | 1974 | 608 | 0.000 |
Why?
| | Peptide Hydrolases | 1 | 1989 | 112 | 0.000 |
Why?
| | Cell Division | 1 | 1989 | 795 | 0.000 |
Why?
| | Extracellular Matrix | 1 | 1989 | 528 | 0.000 |
Why?
|
|
Dreskin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|